BridgeBio Pharma Approves Employee Equity Grants

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 5 days ago

0mins

BBIO-3.65%

Should l Buy BBIO?

Source: Newsfilter

Equity Grant Program: On February 12, 2026, BridgeBio Pharma approved equity grants totaling 76,701 restricted stock units to 34 new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in genetic drug development.
Vesting Schedule: One-fourth of the restricted stock units will vest on February 16, 2027, with the remaining shares vesting quarterly, ensuring employees remain with the company to receive their incentives, which boosts employee loyalty and motivation.
Compliance and Plan Background: The equity grants comply with Nasdaq Listing Rule 5635(c)(4) and are granted under an incentive plan adopted in November 2019, demonstrating the company's strategic planning and compliance in talent acquisition.
Company Mission and Vision: BridgeBio focuses on developing transformative medicines for genetic conditions, aiming to bridge the gap between advancements in genetic science and patient needs, utilizing a decentralized operational model to enhance R&D efficiency and market responsiveness.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BBIO

Wall Street analysts forecast BBIO stock price to rise

13 Analyst Rating

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 70.720

Low

85.00

Averages

98.50

High

157.00

Current: 70.720

Low

85.00

Averages

98.50

High

157.00

H.C. Wainwright

Raghuram Selvaraju

maintain

$90 -> $100

2026-02-17

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$90 -> $100

AI Analysis

2026-02-17

maintain

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BridgeBio to $100 from $90 and keeps a Buy rating on the shares. The firm cites the positive top-line results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, for the target boost.

Oppenheimer

Trevor Allred

Outperform

maintain

$81 -> $83

2026-02-13

Reason

Oppenheimer

Trevor Allred

Price Target

$81 -> $83

2026-02-13

maintain

Outperform

Reason

Oppenheimer analyst Trevor Allred raised the firm's price target on BridgeBio to $83 from $81 and keeps an Outperform rating on the shares. The firm says Phase 3 result demonstrated 1.74cm/year least-squares mean AGH improvement, which compares favorably to vosoritide/navepegritide results of 1.5-1.6cm/year, though perhaps incrementally disappoints vs. Propel 2 results. Hyperphosphatemia results may assuage concerns on safety, with only three subjects demonstrating mild, transient hyperphosphatemia, though concerns on long-term utilization may limit total commercial uptake, Oppenheimer adds. The firm considers the results in line with its thesis, and believes efficacy should support infigratinib as best-in-class drug with skewed uptake in the U.S. market vs. ex-U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBIO

Unlock Now

About BBIO

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Worst Performing Large-Cap Stocks Last Week

12 hours agoBenzinga

GPC Earnings Miss: Genuine Parts Company (NYSE:GPC) saw a 19.51% drop this week after reporting disappointing fourth-quarter results and issuing FY26 EPS guidance below estimates, prompting multiple analysts to lower their price targets, indicating market concerns over its future profitability.
FLUT Earnings Awaited: Flutter Entertainment plc (NYSE:FLUT) decreased by 11.86% this week as the company announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, leading investors to adopt a cautious stance ahead of the earnings report, which may impact stock performance.
OKTA Price Target Cuts: Okta, Inc. (NASDAQ:OKTA) fell 12.86% this week after several firms lowered their price targets, reflecting diminished market confidence in its growth potential and possibly prompting investors to reassess its investment value.
TEAM Executive Change: Atlassian Corporation (NASDAQ:TEAM) decreased by 5.33% this week following the announcement of James Chuong as the new Chief Financial Officer effective March 30, 2026; while executive changes may bring new strategic directions, they failed to boost the stock price in the short term.

Cormorant Increases MoonLake Stake Above 6%

4 days agostocktwits

Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.